SEC EDGARAUG 132 min read$TAK

Plump Andrew Stewart sold $2.8M of TAK

Plump Andrew Stewart (President, R&D) sold 165,393 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($2.83M total) on 2026-08-10.

Original reporting

SEC EDGAR · Plump Andrew Stewart

Published Aug 13, 2026, 1:50 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TAK

Neutral

medium confidence

Mentioned

$TAK

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TAKNeutralLow

Why it matters

This provides a fresh, primary-source datapoint on insider selling activity, but it does not include any new company-specific business or financial developments.

Market read

Traders may monitor insider activity as a sentiment input, but the filing alone is unlikely to drive a fundamental repricing.

What to watch

The filing does not state reasons for the sale, and the share price level ($17.10) may reflect normal trading rather than a new valuation signal.

Relevance 6/10Novelty 3/10Timing: filed Aug 12, transaction dated Aug 10 (insider sale disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd (TAK).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TAKNeutralMedium confidence

Context

Takeda disclosed an insider open-market sale by its R&D President, Andrew Stewart, of 165,393 shares at $17.10 on Aug 10.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst from the filing alone.

Evidence & confidence

Form 4 shows an open-market sale and explicitly notes no pre-arranged 10b5-1 plan, but it does not provide new operational, financial, or regulatory information.

Market effects

Sector

Minimal; insider sale does not change sector fundamentals or guidance.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan could be interpreted as less “mechanical,” but insider sales are still often driven by diversification or personal liquidity needs.

Key entities

issuer
TAK
Takeda Pharmaceutical Co Ltd, the subject of the Form 4 insider transaction.
insider
Plump Andrew Stewart
President, R&D at Takeda, reported an open-market sale of shares.

Read at source ← All news

OCT 6

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

hcplive.com2 min

OCT 3

$PFEHighAI 9/10

Targeted Drug Duo with Lighter Chemotherapy Delivers 97% Survival in

A phase 2 trial showed a regimen combining brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved 92% complete response and 97% 2-year progression-free survival in early-stage Hodgkin lymphoma. The study, published in Advances in Therapy, involved 154 patients and was funded by Seagen (now Pfizer), Takeda, and Bristol-Myers Squibb.

bioengineer.org3 min

OCT 2

$BIIBMed

CMS's GLOBE Drug Pricing Plan Collapses to $400M in Savings, Leaving a Four-Company Test

CMS's GLOBE drug pricing plan's projected savings dropped from $11.9B to $400M, affecting about four manufacturers, including Biogen, Takeda, and Daiichi Sankyo. The reduction is due to exclusions for GARD participants. The final rule may face legal challenges and has raised concerns about its effectiveness.

finance.biggo.com4 min

SEP 30

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

ajmc.com3 min

SEP 30

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

intelligencer.ca2 min

SEP 22